Allergy, Asthma & Respiratory Disease

The Korean Academy of Asthma, Allergy and Clinical Immunology (대한천식알레르기학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical analysis of risk factors in refractory mycoplasma pneumonia in children

소아에서 치료 불응성 미코플라스마 폐렴의 위험 인자에 대한 임상적 분석

  • Choi, Seo Yeol (Department of Pediatrics, Dankook University College of Medicine) ;
  • Seo, Ju-Hee (Department of Pediatrics, Dankook University College of Medicine) ;
  • Lee, Kunsong (Department of Pediatrics, Dankook University College of Medicine) ;
  • Choi, Qute (Department of Laboratory Medicine, Dankook University College of Medicine)
  • 최서열 (단국대학교 의과대학 소아과학교실) ;
  • 서주희 (단국대학교 의과대학 소아과학교실) ;
  • 이건송 (단국대학교 의과대학 소아과학교실) ;
  • 최규태 (단국대학교 의과대학 진단검사의학과교실)
  • Received : 2017.06.28
  • Accepted : 2017.08.30
  • Published : 2018.01.31
⟨ Previous Next ⟩

Abstract

Purpose: Refractory Mycoplasma pneumonia (RMP) has been increasing not only in Korea but worldwide. We investigated the incidence of M. pneumonia resistant to macrolides and risk factors for RMP. Methods: From October 2015 to May 2016, 62 pediatric patients who were admitted due to pneumonia diagnosed on the basis of chest x-ray with respiratory symptoms and positive for M. pneumoniae in polymerase chain reaction with no evidence of other bacterial or viral infections were included. Sequence analysis of the 23S rRNA gene in M. pneumoniae was performed to identify macrolide resistance. Patients with congenital anomalies, history of pulmonary disease, and unclear information on antibiotic use were excluded. Results: Mutations in the 23S rRNA gene were detected in 50 of 62 patients (80.6%). Risk factors were analyzed in only 45 patients. The RMP group consisted of 26 patients (57.8%) who had fever lasting more than 5 days and deteriorating chest x-ray findings. The lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels were significantly higher in the RMP group than in the non-RMP group (LDH: $300{\pm}79U/L$ vs. $469{\pm}206U/L$, CRP: $4.9{\pm}4.3mg/dL$ vs. $2.5{\pm}1.7mg/dL$; P= 0.04 vs. P= 0.026). In univariate analysis, the RMP group was significantly associated with 23S rRNA gene mutation, lobar pneumonia, and pleural effusion (odds ration [OR]: 10.8, 4.1, 5.3; P= 0.004, P= 0.036, P= 0.046). The presence of macrolide resistance was found to be only a significant risk factor in logistic regression (OR; 8.827; 95% confidence interval, 1.376-56.622; P= 0.022). Conclusion: Macrolide resistance was a significant risk factor in patients with RMP and identification of macrolide resistance might be helpful in predicting RMP and establishing target therapy for RMP.

Keywords

References

  1. Kim EK, Youn YS, Rhim JW, Shin MS, Kang JH, Lee KY. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr 2015;58:172-7. https://doi.org/10.3345/kjp.2015.58.5.172
  2. Kim JW, Seo HK, Yoo EG, Park SJ, Yoon SH, Jung HY, et al. Mycoplasma pneumoniae pneumonia in Korean children, from 1979 to 2006: a meta-analysis. Korean J Pediatr 2009;52:315-23. https://doi.org/10.3345/kjp.2009.52.3.315
  3. Shin JE, Cheon BR, Shim JW, Kim DS, Jung HL, Park MS, et al. Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma. Korean J Pediatr 2014;57:271-7. https://doi.org/10.3345/kjp.2014.57.6.271
  4. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014;6:22-6. https://doi.org/10.4168/aair.2014.6.1.22
  5. Shah SS, Test M, Sheffler-Collins S, Weiss AK, Hall M. Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with Mycoplasma pneumoniae pneumonia. J Hosp Med 2012;7:311-7. https://doi.org/10.1002/jhm.1904
  6. Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012;17:354-62. https://doi.org/10.1111/j.1440-1843.2011.02102.x
  7. Wang M, Wang Y, Yan Y, Zhu C, Huang L, Shao X, et al. Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children. Int J Infect Dis 2014;29:18-23. https://doi.org/10.1016/j.ijid.2014.07.020
  8. Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One 2016;11:e0156465. https://doi.org/10.1371/journal.pone.0156465
  9. Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 2013;68:506-11. https://doi.org/10.1093/jac/dks457
  10. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53:2158-9. https://doi.org/10.1128/AAC.01563-08
  11. Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 2013;19:1281-4. https://doi.org/10.3201/eid1908.121455
  12. Lee E, Cho HJ, Hong SJ, Lee J, Sung H, Yu J. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr 2017;60:151-7. https://doi.org/10.3345/kjp.2017.60.5.151
  13. Cheong KN, Chiu SS, Chan BW, To KK, Chan EL, Ho PL. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect 2016;49:127-30. https://doi.org/10.1016/j.jmii.2014.11.003
  14. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children. Respir Care 2015;60:1469-75. https://doi.org/10.4187/respcare.03920
  15. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004;48:4624-30. https://doi.org/10.1128/AAC.48.12.4624-4630.2004
  16. Oh CE, Choi EH, Lee HJ. Detection of genetic mutations associated with macrolide resistance of Mycoplasma pneumoniae. Korean J Pediatr 2010; 53:178-83. https://doi.org/10.3345/kjp.2010.53.2.178
  17. Kim JH, Kim JY, Yoo CH, Seo WH, Yoo Y, Song DJ, et al. Macrolide resistance and its impacts on M. peumoniae pneumonia in children: comparison of two recent epidemics in Korea. Allergy Asthma Immunol Res 2017;9:340-6. https://doi.org/10.4168/aair.2017.9.4.340
  18. Yu J. Clinical issues regarding increased macrolide-resistant Mycoplasma pneumoniae in children. Allergy Asthma Respir Dis 2017;5:1-2. https://doi.org/10.4168/aard.2017.5.1.1
  19. Morozumi M, Okada T, Tajima T, Ubukata K, Iwata S. Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. Int J Antimicrob Agents 2017;50:255-7. https://doi.org/10.1016/j.ijantimicag.2017.02.027
  20. Shan LS, Liu X, Kang XY, Wang F, Han XH, Shang YX. Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children. World J Pediatr 2017;13:321-7. https://doi.org/10.1007/s12519-017-0014-9

Cited by

  1. 마행감석탕의 소아 마이코플라즈마 폐렴 치료에 대한 체계적 문헌 고찰 및 메타분석 vol.34, pp.2, 2018, https://doi.org/10.7778/jpkm.2020.34.2.90